Improving hidradenitis suppurativa management: consensus statements from physicians and patients' perspectives.
Biologics
HS-unit
Multidisciplinary approach
Patient’s journey
Quality of life
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
24 Aug 2024
24 Aug 2024
Historique:
received:
05
06
2024
accepted:
05
08
2024
revised:
05
06
2024
medline:
24
8
2024
pubmed:
24
8
2024
entrez:
24
8
2024
Statut:
epublish
Résumé
Hidradenitis suppurativa (HS) is a frequent chronic inflammatory skin condition primarily affecting areas rich in apocrine sweat glands, presenting with comedones, papules, nodules, and abscesses, as well as tunnels and hypertrophic scarring. Despite its prevalence and impact on quality of life, the pathogenesis of HS remains incompletely understood. Notably, its diagnosis often suffers from delays and misidentification, therefore an improved education for healthcare providers is mandatory. Moreover, HS is frequently associated with systemic comorbidities and a multidisciplinary approach is suggested for its management. Recognizing these challenges, a group of Italian HS experts and patients convened to develop consensus guidelines via the Nominal Group Technique. Through iterative meetings and remote collaboration, they identified key areas for improvement and formulated consensus statements to guide healthcare providers in delivering optimal care. This collaborative effort highlights the importance of standardized approaches and interdisciplinary collaboration in managing HS effectively.
Identifiants
pubmed: 39180694
doi: 10.1007/s00403-024-03316-2
pii: 10.1007/s00403-024-03316-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
577Informations de copyright
© 2024. The Author(s).
Références
Zouboulis CC et al (2020) What causes hidradenitis suppurativa?–15 years after. Exp Dermatol 29(12):1154–1170
pubmed: 33058306
doi: 10.1111/exd.14214
Antonelli F et al (2023) Clinical features and response to treatment in elderly subjects affected by hidradenitis suppurativa: a cohort study. J Clin Med 12(24):7754
pubmed: 38137823
pmcid: 10744325
doi: 10.3390/jcm12247754
Frew JW et al (2021) A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol 141(2):316–324
pubmed: 32919760
doi: 10.1016/j.jid.2020.06.019
Marzano AV et al (2022) Whole-exome sequencing in 10 unrelated patients with syndromic hidradenitis suppurativa: a preliminary step for a genotype-phenotype correlation. Dermatology 238(5):860–869
pubmed: 35034021
doi: 10.1159/000521263
Moltrasio C et al (2022) Hidradenitis suppurativa: a perspective on genetic factors involved in the disease. Biomedicines 10(8):2039
pubmed: 36009585
pmcid: 9406067
doi: 10.3390/biomedicines10082039
Saunte DML, Jemec GBE (2017) Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318(20):2019–2032
pubmed: 29183082
doi: 10.1001/jama.2017.16691
Collier E et al (2020) Special considerations for women with hidradenitis suppurativa. Int J Womens Dermatol 6(2):85–88
pubmed: 32258337
pmcid: 7105653
doi: 10.1016/j.ijwd.2020.02.005
Johnston LA et al (2022) Practical guidelines for managing patients with hidradenitis suppurativa: an update. J Cutan Med Surg 26(2):2S-24S
pubmed: 36000460
doi: 10.1177/12034754221116115
Saunte DM et al (2015) Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 173(6):1546–1549
pubmed: 26198191
doi: 10.1111/bjd.14038
Chadha SA et al (2023) Assessing unmet needs in patients with hidradenitis suppurativa. Arch Dermatol Res 315(9):2555–2560
pubmed: 37264285
doi: 10.1007/s00403-023-02645-y
Daoud M et al (2023) Overview and comparison of the clinical scores in hidradenitis suppurativa: a real-life clinical data. Front Med (Lausanne) 10:1145152
pubmed: 37138732
doi: 10.3389/fmed.2023.1145152
Pescitelli L, Ricceri F, Prignano F (2018) Hidradenitis suppurativa and associated diseases. G Ital Dermatol Venereol 153(3):8–17
pubmed: 30468375
Sabat R et al (2020) Hidradenitis suppurativa. Nat Rev Dis Primers 6(1):18
pubmed: 32165620
doi: 10.1038/s41572-020-0149-1
Saito-Sasaki N, Sawada Y (2023) The development of systemic inflammatory diseases in hidradenitis suppurativa. Diagn (Basel) 13(3):502
Smith MK et al (2017) Hidradenitis suppurativa: an update on connecting the tracts. F1000Res 6:1272
pubmed: 28794864
pmcid: 5538037
doi: 10.12688/f1000research.11337.1
Alter M (2024) Hidradenitis suppurativa. Dermatologie (Heidelb)
Bettoli V et al (2016) Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: evidence from the national Italian registry. Br J Dermatol 174(1):195–197
pubmed: 25913460
doi: 10.1111/bjd.13864
Ocker L et al (2022) Current medical and surgical treatment of hidradenitis suppurativa—a comprehensive review. J Clin Med 11(23):7240
pubmed: 36498816
pmcid: 9737445
doi: 10.3390/jcm11237240
Gallagher M et al (1993) The nominal group technique: a research tool for general practice? Fam Pract 10(1):76–81
pubmed: 8477899
doi: 10.1093/fampra/10.1.76
McMillan SS, King M, Tully MP (2016) How to use the nominal group and delphi techniques. Int J Clin Pharm 38(3):655–662
pubmed: 26846316
pmcid: 4909789
Gustafson DH, Shukla RK, Delbecq A, Walster GW (1973) A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, delphi groups, and nominal groups. Organ Behav Hum Perform 9:280
doi: 10.1016/0030-5073(73)90052-4
Rowe G, Wright G (2001) Expert opinions in forecasting: role of the delphi technique. Princ Forecast 30:125
doi: 10.1007/978-0-306-47630-3_7
Jones J, Hunter D (1995) Consensus methods for medical and health services research. BMJ 311(7001):376–380
pubmed: 7640549
pmcid: 2550437
doi: 10.1136/bmj.311.7001.376
Gallego D, Bueno S (2014) Exploring the application of the delphi method as a forecasting tool in information systems and technologies research. Technol Anal Strateg Manag 26:987
doi: 10.1080/09537325.2014.941348
Kaplan MF (1987) The influencing process in group decision making. Group processes. Sage Publications, Inc, Thousand oaks
Snyder CL, Chen SX, Porter ML (2023) Obstacles to Early diagnosis and treatment of hidradenitis suppurativa: current perspectives on improving clinical management. Clin Cosmet Investig Dermatol 16:1833–1841
pubmed: 37483473
pmcid: 10361090
doi: 10.2147/CCID.S301794
Chiricozzi A et al (2018) The hidradenitis suppurativa (HS) “multidisciplinary unit”: a rationale and practical proposal for an organised clinical approach. Eur J Dermatol 28(2):274–275
pubmed: 29619988
doi: 10.1684/ejd.2018.3254
Chiricozzi A, Micali G, Veraldi S (2019) The patient journey: a voyage from diagnosis to hidradenitis suppurativa multidisciplinary unit. J Eur Acad Dermatol Venereol 33(6):15–20
pubmed: 31535760
doi: 10.1111/jdv.15850
van der Zee HH, Jemec GB (2015) New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes. J Am Acad Dermatol 73(5):S23–S26
pubmed: 26470610
doi: 10.1016/j.jaad.2015.07.047
Scala E et al (2021) Hidradenitis suppurativa: where we are and where we are going. Cells 10(8):1013
doi: 10.3390/cells10082094
Margesson LJ, Danby FW (2014) Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol 28(7):1013–1027
pubmed: 25214437
doi: 10.1016/j.bpobgyn.2014.07.012
Zouboulis CC et al (2017) Development and validation of the International hidradenitis suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 177(5):1401–1409
pubmed: 28636793
doi: 10.1111/bjd.15748
Tzellos T et al (2023) Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol 37(2):395–401
pubmed: 36184889
doi: 10.1111/jdv.18632
Timila Touhouche A et al (2020) Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice. Int J Womens Dermatol 6(3):164–168
pubmed: 32637537
pmcid: 7330447
doi: 10.1016/j.ijwd.2020.02.006
Otten M et al (2023) Measuring quality of life in hidradenitis suppurativa: development and validation of a disease-specific patient-reported outcome measure for practice and research. Acta Derm Venereol 103:adv00859
pubmed: 36129249
doi: 10.2340/actadv.v102.2485
Matusiak L, Bieniek A, Szepietowski JC (2010) Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 90(3):264–268
pubmed: 20526543
doi: 10.2340/00015555-0866
Rymaszewska JE et al (2023) Satisfaction with life and coping strategies among patients with hidradenitis suppurativa: a cross-sectional study. J Clin Med 12(8):2775
doi: 10.3390/jcm12082755
Bettoli V et al (2016) The hidradenitis suppurativa patient journey in Italy: current status, unmet needs and opportunities. J Eur Acad Dermatol Venereol 30(11):1965–1970
pubmed: 27136185
doi: 10.1111/jdv.13687
Kashetsky N et al (2022) Patient experiences with hidradenitis suppurativa: the hidradenitis patient experience survey. Clin Exp Dermatol 47(1):72–79
pubmed: 34235774
doi: 10.1111/ced.14826
Tang B et al (2023) Complications of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. Int Wound J 20(4):1253–1261
pubmed: 36207796
doi: 10.1111/iwj.13945
Rompel R, Petres J (2000) Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 26(7):638–643
pubmed: 10886270
doi: 10.1046/j.1524-4725.2000.00043.x
Lacarrubba F et al (2018) Role of the imaging techniques in the diagnosis and staging of hidradenitis suppurativa. G Ital Dermatol Venereol 153(3):20–25
pubmed: 30468377
Srisajjakul S, Prapaisilp P, Bangchokdee S (2022) Magnetic resonance imaging of hidradenitis suppurativa: a focus on the anoperineal location. Korean J Radiol 23(8):785–793
pubmed: 35914743
pmcid: 9340234
doi: 10.3348/kjr.2022.0215
Wortsman X (2016) Imaging of hidradenitis suppurativa. Dermatol Clin 34(1):59–68
pubmed: 26617359
doi: 10.1016/j.det.2015.08.003
Mazeika E, Jariene V, Valiukeviciene S (2021) Medical infrared thermography as hidradenitis suppurativa diagnostic tool: literature review. Postepy Dermatol Alergol 38(2):32–35
pubmed: 34408563
pmcid: 8362785
doi: 10.5114/ada.2021.104274
Nazary M et al (2011) Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol 672(1–3):1–8
pubmed: 21930119
doi: 10.1016/j.ejphar.2011.08.047
Vellaichamy G et al (2022) Recent advances in hidradenitis suppurativa: role of race, genetics, and immunology. Front Genet 13:918858
pubmed: 36092908
pmcid: 9458948
doi: 10.3389/fgene.2022.918858
Diaz MJ et al (2023) Hidradenitis suppurativa: molecular etiology, pathophysiology, and management—a systematic review. Curr Issues Mol Biol 45(5):4400–4415
pubmed: 37232749
pmcid: 10217408
doi: 10.3390/cimb45050280
Zouboulis CC et al (2015) European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 29(4):619–644
pubmed: 25640693
doi: 10.1111/jdv.12966
Blum FR, DeBarmore BM, Sayed CJ (2023) Hidradenitis suppurativa in older adults. JAMA Dermatol 159(2):216–219
pubmed: 36515944
doi: 10.1001/jamadermatol.2022.5390
Liy-Wong C et al (2021) Hidradenitis suppurativa in the pediatric population: an international, multicenter, retrospective, cross-sectional study of 481 pediatric patients. JAMA Dermatol 157(4):385–391
pubmed: 33625473
doi: 10.1001/jamadermatol.2020.5435
Rosi E et al (2022) Hidradenitis suppurativa: the influence of gender, the importance of trigger factors and the implications for patient habits. Biomedicines 10(11):2973
pubmed: 36428540
pmcid: 9687269
doi: 10.3390/biomedicines10112973
Chu CB, Yang CC, Tsai SJ (2021) Hidradenitis suppurativa: disease pathophysiology and sex hormones. Chin J Physiol 64(6):257–265
pubmed: 34975118
doi: 10.4103/cjp.cjp_67_21
Kozera EK et al (2021) Clinical considerations in the management of hidradenitis suppurativa in women. Int J Womens Dermatol 7(5):664–671
pubmed: 35028361
pmcid: 8714605
doi: 10.1016/j.ijwd.2021.10.012
Lyons AB et al (2020) Evaluation of hidradenitis suppurativa disease course during pregnancy and postpartum. JAMA Dermatol 156(6):681–685
pubmed: 32347884
doi: 10.1001/jamadermatol.2020.0777
Tugnoli S et al (2020) Anger, emotional fragility, self-esteem, and psychiatric comorbidity in patients with hidradenitis suppurativa/acne inversa. J Clin Psychol Med Settings 27(3):527–540
pubmed: 31222671
doi: 10.1007/s10880-019-09640-4
Jedrzejczak MJ et al (2021) Expert knowledge, attitudes, and practices in management of hidradenitis suppurativa pain. JAMA Dermatol 157(4):464–466
pubmed: 33625467
pmcid: 7905694
doi: 10.1001/jamadermatol.2020.5857
Wlodarek K et al (2020) Psychosocial burden of hidradenitis suppurativa patients’ partners. J Eur Acad Dermatol Venereol 34(8):1822–1827
pubmed: 32003871
doi: 10.1111/jdv.16255
Narla S, Lyons AB, Hamzavi IH (2020) The most recent advances in understanding and managing hidradenitis suppurativa. F1000Res 9:1049
doi: 10.12688/f1000research.26083.1
Zouboulis CC, Chernyshov PV (2021) Hidradenitis suppurativa-specific, patient-reported outcome measures. J Eur Acad Dermatol Venereol 35(7):1420–1421
pubmed: 34139050
doi: 10.1111/jdv.17306
Kirby JS et al (2020) The hidradenitis suppurativa quality of life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol 183(2):340–348
pubmed: 31705538
doi: 10.1111/bjd.18692
Zouboulis CC (2021) Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument. Br J Dermatol 184(6):1203–1204
pubmed: 33492666
doi: 10.1111/bjd.19798
Maronese CA et al (2024) Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol 20(5):525–545
pubmed: 38130204
doi: 10.1080/1744666X.2023.2298356
Kimball AB et al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375(5):422–434
pubmed: 27518661
doi: 10.1056/NEJMoa1504370
Kimball AB et al (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 401(10378):747–761
pubmed: 36746171
doi: 10.1016/S0140-6736(23)00022-3
Bimzelx (bimekizumab) EPAR–Medicine overview, Reference Number: EMA/250454/2023 https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx
Garg A et al (2020) Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) Project. J Am Acad Dermatol 82(2):366–376
pubmed: 31279015
doi: 10.1016/j.jaad.2019.06.1301
Alikhan A et al (2019) North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part i: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol 81(1):76–90
pubmed: 30872156
pmcid: 9131894
doi: 10.1016/j.jaad.2019.02.067
Kirby JS et al (2020) A narrative review of the definition of ‘flare’ in hidradenitis suppurativa. Br J Dermatol 182(1):24–28
pubmed: 31025310
doi: 10.1111/bjd.18660
LeWitt TM et al (2022) International consensus definition of disease flare in hidradenitis suppurativa. Br J Dermatol 187(5):785–787
pubmed: 35531746
pmcid: 9633352
doi: 10.1111/bjd.21647
Rathod U et al (2023) Hidradenitis suppurativa: a literature review comparing current therapeutic modalities. Cureus 15(8):e43695
pubmed: 37724217
pmcid: 10505353
Bechara FG et al (2021) Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg 156(11):1001–1009
pubmed: 34406349
doi: 10.1001/jamasurg.2021.3655
Kromann CB et al (2014) Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol 171(4):819–824
pubmed: 24804604
doi: 10.1111/bjd.13090
Sartorius K et al (2009) Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 161(4):831–839
pubmed: 19438453
doi: 10.1111/j.1365-2133.2009.09198.x
Acharya P, Mathur M (2020) Hidradenitis suppurativa and smoking: a systematic review and meta-analysis. J Am Acad Dermatol 82(4):1006–1011
pubmed: 31678467
doi: 10.1016/j.jaad.2019.10.044
Deilhes F et al (2020) Profile of smoking dependency in hidradenitis suppurativa patients and smoking cessation outcomes. J Eur Acad Dermatol Venereol 34(12):e790–e791
pubmed: 32311802
doi: 10.1111/jdv.16494